Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    NEXT STORY
    Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
    PREV STORY
    Digital Radiography Market to Reach US$ 2,978.3 Mn by 2026, FDA Clearance to Philips and Other Companies to Enable Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene to Present at the 2018 UBS Global Healthcare Conference

    CAMBRIDGE, Mass. and BEIJING, China, May 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News

    Coloplast delivers 8% organic revenue growth and upgrades full-year growth expectations

    Coloplast delivered 8% organic revenue growth and a 31% EBIT margin at constant exchange ...

    author_avatar
    NASDAQ Market News

    Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy

    CAMBRIDGE, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer ...

    author_avatar
    NASDAQ Market News